Shire PLC is a biotech company incorporated and registered in Jersey on January 28, 2008. The Company is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines for patients with rare diseases and other select conditions. The Company offers products including VYVANSE a pro-drug stimulant for the treatment of ADHD a chronic neurobehavioral disorder; ADDERALL XR is an extended release treatment for ADHD, which uses MICROTROL drug delivery technology and is designed to provide once-daily dosing; INTUNIV an alpha-2A receptor agonist indicated for the treatment of ADHD; LIALDA for the induction of remission in patients with mild to moderately active UC and for the maintenance of remission of Ulcerative Colitis (UC); PENTASA is an ethylcellulose-coated, controlled release capsule formulation designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract; REPLAGAL is marketed for the treatment of Fabry disease outside of the U.S. Fabry disease is a rare, inherited genetic disorder resulting from a deficiency in the activity of the lysosomal enzyme alpha-galactosidase A, which is involved in the breakdown of fats; ELAPRASE a treatment for Hunter syndrome (also known as Mucopolysaccharidosis Type II or MPS II); VPRIV a treatment for Type 1 Gaucher disease; FIRAZYR a peptide-based therapeutic developed for the symptomatic treatment of acute attacks of HAE; CINRYZE a C1 esterase inhibitor therapy for routine prophylaxis against HAE, also known as C1 inhibitor (C1-INH) deficiency; GATTEX/REVESTIVE for injection is the first prescription medicine for the long-term treatment of adults with SBS who are dependent on parenteral support; NATPARA (parathyroid hormone) for injection is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with HPT; FOSRENOL a phosphate binder that is indicated for use in patients with end-stage renal disease (stage 5) receiving dialysis and, is also indicated in the EU for the treatment of adult patients with Chronic kidney disease. The Company also offers other products including KALBITOR a plasma kallikrein (pKal) inhibitor for the treatment of acute attacks of HAE in patients 12 years of age and older. The clinical development, manufacturing and marketing of the Company's products is subject to governmental regulation in the United States, the EU and other territories.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.